Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial

A securities class action lawsuit has been filed against Rocket Pharmaceuticals (RCKT) on behalf of investors who purchased shares between February 27, 2025, and May 26, 2025, alleging the company made false and misleading statements regarding the safety and clinical trial protocol of its RP-A501 therapy. The lawsuit follows a 62% crash in RCKT's stock price on May 27, 2025, after the FDA placed a clinical hold on the Phase 2 trial due to a patient's death and the company's prior undisclosed amendment to the trial protocol, including the introduction of a novel immunomodulatory agent.

Analysis

Rocket Pharmaceuticals (RCKT) is facing a securities class action lawsuit (Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049) filed on behalf of investors who acquired securities between February 27, 2025, and May 26, 2025. This legal action, coupled with an extremely negative sentiment score of -0.9, follows a catastrophic 62% decline ($3.94 per share) in RCKT's stock price on May 27, 2025. The crash was triggered by the company's announcement of an FDA clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy for Danon disease, after a patient experienced a Serious Adverse Event (SAE) and subsequently died. The lawsuit alleges that Rocket Pharmaceuticals made materially false and misleading statements, failing to disclose the true safety profile and clinical trial protocol for RP-A501, the known risk of SAEs including patient deaths, and that the company had amended the trial protocol "several months ago" to include a novel immunomodulatory agent without prior notification to investors or, allegedly, the FDA. This lack of transparency was highlighted when management revealed the protocol amendment during an update call on May 27, 2025, apparently surprising analysts. The market impact score of 0.7 underscores the significance of this event. Furthermore, an external AI-driven stock analysis tool, InvestingPro, reportedly did not identify RCKT as a top-ranked stock for potential upside, adding a layer of caution from a quantitative perspective. The lead plaintiff deadline for the lawsuit is August 11, 2025.

Key Decisions for Investors

• Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, and suffered substantial losses should consider contacting the law firm Hagens Berman by the August 11, 2025, lead plaintiff deadline to understand their options regarding the class action lawsuit.
• Extreme caution is warranted for both current and prospective investors due to the significant uncertainty stemming from the FDA clinical hold on a key asset (RP-A501), the ongoing litigation alleging serious misrepresentation, and concerns over the company's historical transparency regarding trial protocols and safety signals.
• Closely monitor developments related to the FDA's review of the RP-A501 clinical hold, the progress and potential outcomes of the securities class action lawsuit, and any further company disclosures or independent analyses concerning the amended trial protocol and its implications for RP-A501's future.